Document Detail


New developments in secondary stroke prevention: impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on clinical management.
MedLine Citation:
PMID:  18035244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.
Authors:
Helmi L Lutsep
Related Documents :
16864834 - Door to thrombolysis: er reorganization and reduced delays to acute stroke treatment.
16936384 - Methylenetetrahydrofolate reductase gene polymorphism in indian stroke patients.
17344774 - Characteristics of patients admitted with stroke.
17689384 - Should routine echocardiography be performed in all patients with stroke?
22452804 - The prevalence, risk factors and prognosis of aspirin resistance in elderly male patien...
8722844 - Comparison of the efficacy of amphotericin b and fluconazole in the treatment of crypto...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association     Volume:  16     ISSN:  1532-8511     ISO Abbreviation:  J Stroke Cerebrovasc Dis     Publication Date:    2007 Nov-Dec
Date Detail:
Created Date:  2007-11-23     Completed Date:  2008-01-08     Revised Date:  2009-01-16    
Medline Journal Info:
Nlm Unique ID:  9111633     Medline TA:  J Stroke Cerebrovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  263-7     Citation Subset:  IM    
Affiliation:
Department of Neurology, Oregon Health and Science University, Oregon Stroke Center, Portland, OR 97239, USA. lutseph@ohsu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aspirin / adverse effects,  therapeutic use*
Australasia
Brain Ischemia / complications*,  drug therapy
Delayed-Action Preparations
Dipyridamole / adverse effects,  therapeutic use*
Drug Therapy, Combination
Europe
Hemorrhage / chemically induced
Humans
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Practice Guidelines as Topic
Recurrence / prevention & control
Stroke / drug therapy*,  etiology,  prevention & control
Treatment Outcome
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 58-32-2/Dipyridamole
Comments/Corrections
Erratum In:
J Stroke Cerebrovasc Dis. 2008 Sep;17(5):330

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Controversy of surgical treatment for severe cerebellar infarction.
Next Document:  Case of moyamoya disease in a patient with advanced acquired immunodeficiency syndrome.